“Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity”, J of Skin, vol. 7, no. 6, p. s274, Nov. 2023, doi: 10.25251/skin.7.supp.274.